diabetes
Diabetes: insulin and other drugs, glucose monitors and insulin pumps.
Theme · 5 companies · 2 report it as a revenue line
ABT Abbott Laboratories
Sells it“Continuous glucose monitoring (CGM) sales were $6.2B versus $5.6B, up 8.3% excluding FX, reflecting continued U.S. and international adoption.”
- Revenue$13.0BYoY +14.5%
- Net income$920.0MYoY −44.0%
JNJ Johnson & Johnson
Sells it“Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration).”
- Revenue$94.2BYoY +6.0%
- Net income$26.8BYoY +90.6%
- Revenue$25.4BYoY +5.9%
- Net income$210.0MYoY −95.9%
LLY Eli Lilly and Company
Sells it 53%, $34.7B a year“A glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, for the treatment of adults with type 2 diabetes in combination with diet and exercise to improve glycemic control.”
- Revenue$65.2BYoY +44.7%
- Net income$20.6BYoY +94.9%
- Revenue$24.4BYoY +38.6%
- Net income$6.5BYoY +15.5%
MDT Medtronic
Sells it“Diabetes growth reflected the U.S. MiniMed Flex launch and international adoption of MiniMed 780G.”
- Revenue$9.8BYoY +13.7%
- Net income$1.5BYoY +41.3%
MRK Merck & Co.
Sells it 4%, $2.5B a year“Januvia (sitagliptin) and Janumet (sitagliptin/metformin HCl) for the treatment of type 2 diabetes.”
- Revenue$65.0BYoY +1.3%
- Net income$18.3BYoY +6.6%
- Revenue$18.1BYoY +4.7%
- Net income$5.1BYoY −12.4%
No companies have a recent 8-K matching these events.
No companies in the selected roles.